TSVC — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Petal is developing an incisionless surgery platform using Millisecond Pulse Histotripsy, a form of focused therapeutic ultrasound that breaks down targeted diseased tissue without incisions, heat, or trauma.
BiotechDeep TechHealthtechMedical DevicesRedwood City, US
Prash Chopra(Founding CEO & Director)Bowen Jiang(Co-founder)Nicholas Theodore(Co-founder & Director)Prashant Chopra(Executive Officer, Director, Promoter)
BoardFrederic Moll(Director)Rony Abovitz(Co-founding Advisor)
Co-investorsShangBay Capital LLCDolma VenturesSonder Futures
Petal offers credit card products aimed at helping people access credit, including those new to credit or with past credit issues, by using their savings and spending data to assess creditworthiness beyond a traditional credit score.
ConsumerFintechOxford, US
David Michael Melnick Taffet(Executive Officer)
Co-investorsAfore CapitalEvolution VC PartnersFairhaven Capital PartnersNelstone VenturesNew Ground VenturesRosecliff Ventures+5 more
Probius develops Quantum Electrochemical Spectroscopy (QES), a label- and reagent-free electrochemical sensing technology that detects and quantifies thousands of analytes—proteins, metabolites, and cells—from microliter-scale biological samples in about 30 minutes.
AI & Machine LearningBiotechDeep TechHardwareHealthtechSemiconductorsFremont, US
Chaitanya Gupta(Executive Officer, Director)inEmmanuel Quevy(Co-founder & CEO)in
Co-investorsCota CapitalHeuristic Capital PartnersSilicon CatalystSocial Starts
Simbryo Technologies is a biotech company that creates endometrial organoids from a patient's own stem cells using a routine biopsy, offering functional diagnostic tests of the uterine lining to assess and optimize endometrial fertility.
AI & Machine LearningBiotechDigital HealthFemTechMedical DevicesHouston, US
Yael Katz(Executive Officer, Director)Aryeh Warmflash(Executive Officer)Stephen Rooks(Director)Andrea Mazzocchi(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.